🕒 Wednesday 15 April 2026 Wed, 15 Apr 2026

Triton Minerals’ maiden drilling at Mozambique’s Aucu Project has validated gold mineralisation across multiple targets, revealing a polymetallic hydrothermal system with notable copper anomalism. The early-stage results set a clear path for systematic follow-up exploration.

New Hope Corporation is raising A$300 million through a new convertible notes issue while simultaneously seeking to repurchase its existing A$300 million notes. The move coincides with elevated thermal coal prices amid Middle East tensions and ongoing operational guidance.

Mamba Exploration has secured a 70% stake in the Meeka East Gold Project following a $2 million placement and completed a major soil sampling program, setting the stage for a maiden drilling campaign pending assay results and approvals.

Noronex completed maiden drilling programs at key uranium and copper projects while bolstering its cash position through strategic asset sales. The company also formalised a 51% stake in its Etango North uranium project and navigates a CEO transition.

Trek Metals has wrapped up the second tranche of its $15 million placement, issuing nearly 9.7 million shares to directors at 15 cents each after shareholder approval. The move bolsters the company’s capital ahead of its drilling campaign at the Kuro manganese prospect.

Temas Resources is tapping the Canadian market with a $1.5 million flow-through share placement aimed at advancing its titanium projects in Quebec. The raise supports exploration expenses tied to its proprietary processing technology and resource development.

Clara Resources has compiled a comprehensive digital geochemistry database from 1980s exploration data, revealing a large-scale gold system at its Mareeba Gold Project in Queensland and setting the stage for maiden drilling in H2 2026.

PYC Therapeutics has secured Safety Review Committee approval to escalate dosing of its investigational drug PYC-001 for Autosomal Dominant Optic Atrophy from single to multiple doses, marking a key step in its clinical development.

Desert Metals Limited has launched a fully underwritten entitlement offer to raise approximately $325,000 through new options, aiming to fund ongoing exploration at its gold prospects in Côte d’Ivoire.

CGN Resources has completed a crucial heritage survey at its Christmas Well gold project, enabling the start of maiden reverse circulation drilling in May across five priority targets. The project hosts multiple promising gold prospects supported by geological and historical data within a prolific gold belt.

Fat Prophets Global Contrarian Fund (ASX: FPC) has disclosed the Dividend Reinvestment Plan (DRP) price for its six-month dividend ending December 2025, applying a 2.5% discount to the volume weighted average price, resulting in a DRP price of AUD 1.35 per share.

Asara Resources (ASX:AS1) is pushing ahead at its Kada Gold Project in Guinea’s prolific Siguiri Basin, boasting a 923,000-ounce gold resource and launching expansive 2026 drilling campaigns aimed at significantly growing both Indicated and Inferred categories.

QEM Limited is set to acquire two past-producing critical mineral projects in Idaho, backed by a $2.645 million placement. The move aligns with US efforts to secure domestic supplies of fluorspar, tungsten, and niobium amid global supply chain vulnerabilities.

Scott Technology delivered a solid HY26 with 7% EBITDA growth to $13 million, driven by strong performances in Materials Handling and Mining, offsetting softness in Protein and Appliances. Forward work rose to $177 million, underpinning expectations for a stronger second half despite geopolitical uncertainties.

Andromeda Metals has wrapped up the Early Works phase at its Great White Project, setting the stage for construction and trimming the equity funding needed for the next development stage to about $40 million.

Ovanti Limited has raised $5.27 million through a discounted placement, aiming to accelerate its global Buy Now Pay Later platform and Super App development with AI integration and merchant expansion.

Marquee Resources (ASX:MQR) has secured a non-exclusive R&D patent licence with Oak Ridge National Laboratory, granting access to NEAREST technology tailored for clay-rich rare earth deposits like Redlings in WA. This partnership could reshape processing efficiency and environmental impact for Marquee’s significant inferred resource.

ReNerve has moved its NervAlign Nerve Guide Matrix into stage 3 of commercial development, a key step toward FDA submission and eventual market entry. This progress supports the company’s ambition to provide surgeons with an alternative to donor nerves for repairing severe peripheral nerve injuries.

Omnia Metals has made a decisive entry into the US critical minerals market by acquiring the Stibnite Ridge antimony and silver project and staking the Radix rare earth and gallium project in Montana, backed by a $1.5 million capital raise.

Australian Unity Office Fund has secured Foreign Investment Review Board approval for the $40 million sale of its Brisbane office tower, setting the stage for a pivotal unitholder meeting to approve the sale, delisting, and wind-up of the fund.

Charger Metals has confirmed significant extensions to spodumene mineralisation at its Medcalf project, with drilling pushing lithium-bearing pegmatites to 600-700m depth and along strike. The company anticipates a substantial resource upgrade following assay results due in the coming weeks.

XRF Scientific posted a 13.8% jump in March quarter revenue to $15.8 million, led by strong international sales and new product shipments. The newly operational India office marks a strategic expansion, setting the stage for further growth.

AuMEGA Metals has closed a C$30.1 million financing round, bolstering its institutional shareholder base and fully funding an expanded 2026 exploration program across its Newfoundland projects.

Noxopharm appoints its Chief Scientific Officer Dr Olivier Laczka as CEO, aiming to capitalise on recent clinical successes and expand the Sofra™ technology’s reach in autoimmune and oncology markets.